Abivax (AAVXF) Research & Development (2022 - 2026)

Abivax has reported Research & Development for 5 years, with the latest figure at -$58.0 million in Q1 2026.

• On a quarterly basis, Research & Development fell 40.3% year-over-year to -$58.0 million in Q1 2026; TTM through Mar 2026 was -$218.2 million, a 81.83% decrease from a year earlier, with the FY2025 full-year figure at -$206.9 million, down 32.15% from the prior year.
• Research & Development was -$58.0 million for Q1 2026 at Abivax, down from -$51.7 million in the prior quarter.
• The five-year high for Research & Development was -$49.28 in Q4 2022, with the low at -$64.8 million in Q3 2025.
• Average Research & Development over 5 years is -$34.3 million, with a median of -$41.3 million recorded in 2025.
• The largest YoY upside for Research & Development was 6.46% in 2025 against a maximum downside of 33013393.13% in 2025.
• Over 5 years, Research & Development stood at -$49.28 in 2022, then plunged by 125.33% to -$111.04 in 2023, then sank by 40.99% to -$156.55 in 2024, then sank by 33013393.13% to -$51.7 million in 2025, then declined by 12.23% to -$58.0 million in 2026.
• The last three Research & Development figures came in at -$58.0 million (Q1 2026), -$51.7 million (Q4 2025), and -$64.8 million (Q3 2025), per Business Quant data.